Eagleeyes的个人主页 - 老虎社区

Eagleeyes

YOLO

IP属地：未知

1关注

0粉丝

0主题

0勋章

2021-11-03

Mirror Cathie Wood investing style

Cathie Wood’s Ark Buys the DIp in Zillow

2021-11-05

$Moderna, Inc.(MRNA)$good opportunity to buy some MRNA today. Hold it until next quarter, with vaccine booster rolls out in the near future expect MRNA to go back to 350 level

2021-11-03

Buy other related vaccine stock like AZN.

抱歉，原内容已删除

2021-11-03

Pfizer best earnings, stock gapped up.To buy other vaccine stock such as AZN. Good opportunity to profit.

This News May Top Anything Else Moderna Says During Its Earnings Report

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4097808049246230","uuid":"4097808049246230","gmtCreate":1634707651204,"gmtModify":1706620623398,"name":"Eagleeyes","pinyin":"eagleeyes","introduction":"","introductionEn":"","signature":"YOLO","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.31","exceedPercentage":"80.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.80%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":846300419,"gmtCreate":1636044189280,"gmtModify":1636047737141,"author":{"id":"4097808049246230","authorId":"4097808049246230","name":"Eagleeyes","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097808049246230","authorIdStr":"4097808049246230"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>good opportunity to buy some MRNA today. Hold it until next quarter, with vaccine booster rolls out in the near future expect MRNA to go back to 350 level","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>good opportunity to buy some MRNA today. Hold it until next quarter, with vaccine booster rolls out in the near future expect MRNA to go back to 350 level","text":"$Moderna, Inc.(MRNA)$good opportunity to buy some MRNA today. Hold it until next quarter, with vaccine booster rolls out in the near future expect MRNA to go back to 350 level","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846300419","isVote":1,"tweetType":1,"viewCount":1004,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848082328,"gmtCreate":1635948310509,"gmtModify":1635948341793,"author":{"id":"4097808049246230","authorId":"4097808049246230","name":"Eagleeyes","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097808049246230","authorIdStr":"4097808049246230"},"themes":[],"htmlText":"Buy other related vaccine stock like AZN.","listText":"Buy other related vaccine stock like AZN.","text":"Buy other related vaccine stock like AZN.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848082328","repostId":"1128259542","repostType":4,"repost":{"id":"1128259542","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635936874,"share":"https://ttm.financial/m/news/1128259542?lang=&edition=full","pubTime":"2021-11-03 18:54","market":"us","language":"en","title":"CVS quarterly sales rise 10% on demand for COVID-19 tests, vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=1128259542","media":"Tiger Newspress","summary":"CVS Health Corp(CVS.N)reported a 10% rise in quarterly sales on Wednesday, as a surge in Delta varia","content":"<p>CVS Health Corp(CVS.N)reported a 10% rise in quarterly sales on Wednesday, as a surge in Delta variant cases across the United States bolstered demand for tests and COVID-19 vaccinations.</p>\n<p>Its&nbsp;shares&nbsp;slid&nbsp;over&nbsp;1%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/307449c61d2bc002f0f0f667e7b25c08\" tg-width=\"777\" tg-height=\"569\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS quarterly sales rise 10% on demand for COVID-19 tests, vaccines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS quarterly sales rise 10% on demand for COVID-19 tests, vaccines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-03 18:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CVS Health Corp(CVS.N)reported a 10% rise in quarterly sales on Wednesday, as a surge in Delta variant cases across the United States bolstered demand for tests and COVID-19 vaccinations.</p>\n<p>Its&nbsp;shares&nbsp;slid&nbsp;over&nbsp;1%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/307449c61d2bc002f0f0f667e7b25c08\" tg-width=\"777\" tg-height=\"569\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVS":"西维斯健康"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128259542","content_text":"CVS Health Corp(CVS.N)reported a 10% rise in quarterly sales on Wednesday, as a surge in Delta variant cases across the United States bolstered demand for tests and COVID-19 vaccinations.\nIts shares slid over 1% in premarket trading.","news_type":1,"symbols_score_info":{"CVS":0.9,"RR1":0.9}},"isVote":1,"tweetType":1,"viewCount":346,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848089377,"gmtCreate":1635948138366,"gmtModify":1635948138434,"author":{"id":"4097808049246230","authorId":"4097808049246230","name":"Eagleeyes","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097808049246230","authorIdStr":"4097808049246230"},"themes":[],"htmlText":"Pfizer best earnings, stock gapped&nbsp;up.To buy other vaccine stock such as AZN. Good&nbsp; &nbsp; &nbsp;opportunity to profit.","listText":"Pfizer best earnings, stock gapped&nbsp;up.To buy other vaccine stock such as AZN. Good&nbsp; &nbsp; &nbsp;opportunity to profit.","text":"Pfizer best earnings, stock gapped up.To buy other vaccine stock such as AZN. Good opportunity to profit.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848089377","repostId":"2180756676","repostType":4,"repost":{"id":"2180756676","kind":"highlight","pubTimestamp":1635936538,"share":"https://ttm.financial/m/news/2180756676?lang=&edition=full","pubTime":"2021-11-03 18:48","market":"us","language":"en","title":"This News May Top Anything Else Moderna Says During Its Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2180756676","media":"Motley Fool","summary":"Moderna's (NASDAQ:MRNA) third-quarter earnings report on Thursday is sure to be chock-full of exciti","content":"<p><b>Moderna</b>'s (NASDAQ:MRNA) third-quarter earnings report on Thursday is sure to be chock-full of exciting numbers and news. Investors are expecting another billion-dollar quarter. That's thanks to sales of the company's coronavirus vaccine. And&nbsp;I'll be watching for details -- such as future vaccine orders -- that could determine Moderna's path moving forward.</p>\n<p>But no matter what Moderna has to say, it will be difficult to top something the company announced last week. Why? This news brings a potential blockbuster product one major step closer to commercialization. In fact, this candidate's next step should be a regulatory submission. Let's take a closer look at what may be Moderna's next billion-dollar revenue driver.</p>\n<h2>The next big product</h2>\n<p>Last week, Moderna said it dosed the first participant in the phase 3 pivotal trial of its cytomegalovirus (CMV) vaccine candidate. This could become Moderna's next big product. CMV is a common virus. For many people it doesn't develop into something serious. But for others, CMV could be devastating. Unborn babies and people with weakened immune systems are most at risk.</p>\n<p>An approved vaccine currently doesn't exist for CMV. And the development programs of most potential competitors are earlier- stage. This means success could offer Moderna the first-to-market advantage. Moderna estimates peak annual revenue for an eventual CMV vaccine would be between $2 billion and $5 billion.</p>\n<p>So, this could be an extremely important product for the biotech company. And as I always say about getting to market first, if healthcare providers are satisfied with the product, they are likely to stick with it.</p>\n<p>Data so far are promising. Moderna's CMV candidate includes six mRNAs that encode for two viral proteins needed to infect. This technique prepares the body to produce an immune response against both proteins.</p>\n<p>Now, exactly how far from commercialization is Moderna? We might think back to coronavirus vaccine development and expect a similar path for the CMV candidate. Unfortunately, investors will have to wait longer this time around. I'll explain.</p>\n<h2>Coronavirus vaccine versus CMV vaccine candidate</h2>\n<p>Coronavirus vaccine development benefited from two elements. First, it was easier than usual to enroll volunteers in clinical trials. Considering the pandemic, many people were eager to try a vaccine -- even in experimental stages. Outside of such extreme situations, it isn't always easy to quickly find participants for a clinical trial.</p>\n<p>That's why it may take longer to enroll a CMV vaccine trial than a coronavirus vaccine one, even if the target number of participants is much lower. For example, for CMV, Moderna plans on enrolling 8,000 participants across 150 sites globally. Moderna enrolled about 30,000 volunteers in its phase 3 coronavirus vaccine trial.</p>\n<p>The second reason the CMV candidate may take longer to reach the market: The U.S. Food and Drug Administration (FDA) offered a fast path to market for COVID-19 vaccine candidates -- Emergency Use Authorization (EUA). The FDA only offers EUAs during public health emergencies such as pandemics. That shortens review time from as long as 10 months to just a few weeks. Moderna, of course, can't apply for emergency authorization for the CMV candidate. So, the potential vaccine won't make it to market nearly as quickly as the coronavirus vaccine.</p>\n<p>What does this mean for investors? We're all interested in Moderna's latest sales and profit numbers. And we want to know what lies ahead for the coronavirus vaccine program. But what may be most important is the next big revenue and profit driver down the road -- outside of the coronavirus program. And if all goes smoothly, that could be the CMV vaccine candidate.</p>\n<p>That's why investors should keep a close eye on any comments from Moderna about its CMV program -- from trial data to regulatory request timeframe. This candidate may be key to Moderna's transformation from coronavirus vaccine company to an mRNA giant that can cover a wide variety of therapeutic areas.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This News May Top Anything Else Moderna Says During Its Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis News May Top Anything Else Moderna Says During Its Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 18:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/03/this-news-may-top-moderna-earnings-news/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna's (NASDAQ:MRNA) third-quarter earnings report on Thursday is sure to be chock-full of exciting numbers and news. Investors are expecting another billion-dollar quarter. That's thanks to sales ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/03/this-news-may-top-moderna-earnings-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/11/03/this-news-may-top-moderna-earnings-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180756676","content_text":"Moderna's (NASDAQ:MRNA) third-quarter earnings report on Thursday is sure to be chock-full of exciting numbers and news. Investors are expecting another billion-dollar quarter. That's thanks to sales of the company's coronavirus vaccine. And I'll be watching for details -- such as future vaccine orders -- that could determine Moderna's path moving forward.\nBut no matter what Moderna has to say, it will be difficult to top something the company announced last week. Why? This news brings a potential blockbuster product one major step closer to commercialization. In fact, this candidate's next step should be a regulatory submission. Let's take a closer look at what may be Moderna's next billion-dollar revenue driver.\nThe next big product\nLast week, Moderna said it dosed the first participant in the phase 3 pivotal trial of its cytomegalovirus (CMV) vaccine candidate. This could become Moderna's next big product. CMV is a common virus. For many people it doesn't develop into something serious. But for others, CMV could be devastating. Unborn babies and people with weakened immune systems are most at risk.\nAn approved vaccine currently doesn't exist for CMV. And the development programs of most potential competitors are earlier- stage. This means success could offer Moderna the first-to-market advantage. Moderna estimates peak annual revenue for an eventual CMV vaccine would be between $2 billion and $5 billion.\nSo, this could be an extremely important product for the biotech company. And as I always say about getting to market first, if healthcare providers are satisfied with the product, they are likely to stick with it.\nData so far are promising. Moderna's CMV candidate includes six mRNAs that encode for two viral proteins needed to infect. This technique prepares the body to produce an immune response against both proteins.\nNow, exactly how far from commercialization is Moderna? We might think back to coronavirus vaccine development and expect a similar path for the CMV candidate. Unfortunately, investors will have to wait longer this time around. I'll explain.\nCoronavirus vaccine versus CMV vaccine candidate\nCoronavirus vaccine development benefited from two elements. First, it was easier than usual to enroll volunteers in clinical trials. Considering the pandemic, many people were eager to try a vaccine -- even in experimental stages. Outside of such extreme situations, it isn't always easy to quickly find participants for a clinical trial.\nThat's why it may take longer to enroll a CMV vaccine trial than a coronavirus vaccine one, even if the target number of participants is much lower. For example, for CMV, Moderna plans on enrolling 8,000 participants across 150 sites globally. Moderna enrolled about 30,000 volunteers in its phase 3 coronavirus vaccine trial.\nThe second reason the CMV candidate may take longer to reach the market: The U.S. Food and Drug Administration (FDA) offered a fast path to market for COVID-19 vaccine candidates -- Emergency Use Authorization (EUA). The FDA only offers EUAs during public health emergencies such as pandemics. That shortens review time from as long as 10 months to just a few weeks. Moderna, of course, can't apply for emergency authorization for the CMV candidate. So, the potential vaccine won't make it to market nearly as quickly as the coronavirus vaccine.\nWhat does this mean for investors? We're all interested in Moderna's latest sales and profit numbers. And we want to know what lies ahead for the coronavirus vaccine program. But what may be most important is the next big revenue and profit driver down the road -- outside of the coronavirus program. And if all goes smoothly, that could be the CMV vaccine candidate.\nThat's why investors should keep a close eye on any comments from Moderna about its CMV program -- from trial data to regulatory request timeframe. This candidate may be key to Moderna's transformation from coronavirus vaccine company to an mRNA giant that can cover a wide variety of therapeutic areas.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":450,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848034995,"gmtCreate":1635947667122,"gmtModify":1635947667225,"author":{"id":"4097808049246230","authorId":"4097808049246230","name":"Eagleeyes","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097808049246230","authorIdStr":"4097808049246230"},"themes":[],"htmlText":"Mirror Cathie Wood investing style","listText":"Mirror Cathie Wood investing style","text":"Mirror Cathie Wood investing style","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848034995","repostId":"2180751345","repostType":4,"repost":{"id":"2180751345","kind":"news","pubTimestamp":1635946174,"share":"https://ttm.financial/m/news/2180751345?lang=&edition=full","pubTime":"2021-11-03 21:29","market":"us","language":"en","title":"Cathie Wood’s Ark Buys the DIp in Zillow","url":"https://stock-news.laohu8.com/highlight/detail?id=2180751345","media":"Bloomberg","summary":"Flagship innovation fund added shares amid Tuesday retreat\nARKK owns more than $600 million stake of","content":"<ul>\n <li>Flagship innovation fund added shares amid Tuesday retreat</li>\n <li>ARKK owns more than $600 million stake of company in turmoil</li>\n</ul>\n<p>Cathie Wood’s flagship exchange-traded fund pounced on a huge slump in <a href=\"https://laohu8.com/S/Z\">Zillow</a> Group Inc. to add more shares of the embattled real estate company.</p>\n<p>The <a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a> (ticker ARKK) bought 288,813 shares of the property firm on Tuesday, according to the daily trading update from Wood’s Ark Investment Management. Zillow plunged over 10% on the day after pulling the plug on its tech-powered home-flipping operation.</p>\n<p>Ark’s purchases were worth around $25 million, based on the closing price.</p>\n<p><img src=\"https://static.tigerbbs.com/e0ed50b6de4eb319f9cdc0c04cede2b8\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"></p>\n<p>Zillow was down again in early trading on Wednesday. The Seattle-based company plans to take writedowns of as much as $569 million and reduce its workforce by 25% as it ditches the algorithm-driven business in the coming months, it said.</p>\n<p>Wood is well known for buying the dip in her high-conviction bets. She and her firm frequently emphasize they have at least a five-year investment horizon, and acknowledge that the disruptive companies they target are often volatile.</p>\n<p>After delivering a 153% return last year, ARKK has lost about 1% in 2021. While its largest holding Tesla Inc. has soared, the fund has been dragged down by other top picks including Zillow, <a href=\"https://laohu8.com/S/ROKU\">Roku Inc</a>. and <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications Inc.</p>\n<p>The $21.8 billion ARKK owns around 7.1 million shares in Zillow worth more than $600 million, according to data compiled by Bloomberg. Wood also owns stakes via the $3.4 billion <a href=\"https://laohu8.com/S/ARKF\">ARK Fintech Innovation ETF</a> (ARKF) and the $5.6 billion <a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a> (ARKW), making her firm Zillow’s fifth-largest shareholder.</p>\n<p>The daily trading updates from Ark show only active decisions by the management team and do not include creation or redemption activity caused by investor flows. For that reason, the firm’s exact trading activity may vary.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s Ark Buys the DIp in Zillow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s Ark Buys the DIp in Zillow\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 21:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-03/cathie-wood-s-ark-grabs-more-zillow-as-real-estate-firm-slumps><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Flagship innovation fund added shares amid Tuesday retreat\nARKK owns more than $600 million stake of company in turmoil\n\nCathie Wood’s flagship exchange-traded fund pounced on a huge slump in Zillow ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-03/cathie-wood-s-ark-grabs-more-zillow-as-real-estate-firm-slumps\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZG":"Zillow Class A","ARKW":"ARK Next Generation Internet ETF","ARKF":"ARK Fintech Innovation ETF","ARKK":"ARK Innovation ETF","Z":"Zillow"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-03/cathie-wood-s-ark-grabs-more-zillow-as-real-estate-firm-slumps","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180751345","content_text":"Flagship innovation fund added shares amid Tuesday retreat\nARKK owns more than $600 million stake of company in turmoil\n\nCathie Wood’s flagship exchange-traded fund pounced on a huge slump in Zillow Group Inc. to add more shares of the embattled real estate company.\nThe ARK Innovation ETF (ticker ARKK) bought 288,813 shares of the property firm on Tuesday, according to the daily trading update from Wood’s Ark Investment Management. Zillow plunged over 10% on the day after pulling the plug on its tech-powered home-flipping operation.\nArk’s purchases were worth around $25 million, based on the closing price.\n\nZillow was down again in early trading on Wednesday. The Seattle-based company plans to take writedowns of as much as $569 million and reduce its workforce by 25% as it ditches the algorithm-driven business in the coming months, it said.\nWood is well known for buying the dip in her high-conviction bets. She and her firm frequently emphasize they have at least a five-year investment horizon, and acknowledge that the disruptive companies they target are often volatile.\nAfter delivering a 153% return last year, ARKK has lost about 1% in 2021. While its largest holding Tesla Inc. has soared, the fund has been dragged down by other top picks including Zillow, Roku Inc. and Zoom Video Communications Inc.\nThe $21.8 billion ARKK owns around 7.1 million shares in Zillow worth more than $600 million, according to data compiled by Bloomberg. Wood also owns stakes via the $3.4 billion ARK Fintech Innovation ETF (ARKF) and the $5.6 billion ARK Next Generation Internet ETF (ARKW), making her firm Zillow’s fifth-largest shareholder.\nThe daily trading updates from Ark show only active decisions by the management team and do not include creation or redemption activity caused by investor flows. For that reason, the firm’s exact trading activity may vary.","news_type":1,"symbols_score_info":{"ARKF":0.9,"ARKK":0.9,"ARKW":0.9,"Z":0.9,"ZG":0.9}},"isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":848034995,"gmtCreate":1635947667122,"gmtModify":1635947667225,"author":{"id":"4097808049246230","authorId":"4097808049246230","name":"Eagleeyes","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097808049246230","authorIdStr":"4097808049246230"},"themes":[],"htmlText":"Mirror Cathie Wood investing style","listText":"Mirror Cathie Wood investing style","text":"Mirror Cathie Wood investing style","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848034995","repostId":"2180751345","repostType":4,"repost":{"id":"2180751345","kind":"news","pubTimestamp":1635946174,"share":"https://ttm.financial/m/news/2180751345?lang=&edition=full","pubTime":"2021-11-03 21:29","market":"us","language":"en","title":"Cathie Wood’s Ark Buys the DIp in Zillow","url":"https://stock-news.laohu8.com/highlight/detail?id=2180751345","media":"Bloomberg","summary":"Flagship innovation fund added shares amid Tuesday retreat\nARKK owns more than $600 million stake of","content":"<ul>\n <li>Flagship innovation fund added shares amid Tuesday retreat</li>\n <li>ARKK owns more than $600 million stake of company in turmoil</li>\n</ul>\n<p>Cathie Wood’s flagship exchange-traded fund pounced on a huge slump in <a href=\"https://laohu8.com/S/Z\">Zillow</a> Group Inc. to add more shares of the embattled real estate company.</p>\n<p>The <a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a> (ticker ARKK) bought 288,813 shares of the property firm on Tuesday, according to the daily trading update from Wood’s Ark Investment Management. Zillow plunged over 10% on the day after pulling the plug on its tech-powered home-flipping operation.</p>\n<p>Ark’s purchases were worth around $25 million, based on the closing price.</p>\n<p><img src=\"https://static.tigerbbs.com/e0ed50b6de4eb319f9cdc0c04cede2b8\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"></p>\n<p>Zillow was down again in early trading on Wednesday. The Seattle-based company plans to take writedowns of as much as $569 million and reduce its workforce by 25% as it ditches the algorithm-driven business in the coming months, it said.</p>\n<p>Wood is well known for buying the dip in her high-conviction bets. She and her firm frequently emphasize they have at least a five-year investment horizon, and acknowledge that the disruptive companies they target are often volatile.</p>\n<p>After delivering a 153% return last year, ARKK has lost about 1% in 2021. While its largest holding Tesla Inc. has soared, the fund has been dragged down by other top picks including Zillow, <a href=\"https://laohu8.com/S/ROKU\">Roku Inc</a>. and <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications Inc.</p>\n<p>The $21.8 billion ARKK owns around 7.1 million shares in Zillow worth more than $600 million, according to data compiled by Bloomberg. Wood also owns stakes via the $3.4 billion <a href=\"https://laohu8.com/S/ARKF\">ARK Fintech Innovation ETF</a> (ARKF) and the $5.6 billion <a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a> (ARKW), making her firm Zillow’s fifth-largest shareholder.</p>\n<p>The daily trading updates from Ark show only active decisions by the management team and do not include creation or redemption activity caused by investor flows. For that reason, the firm’s exact trading activity may vary.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s Ark Buys the DIp in Zillow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s Ark Buys the DIp in Zillow\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 21:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-03/cathie-wood-s-ark-grabs-more-zillow-as-real-estate-firm-slumps><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Flagship innovation fund added shares amid Tuesday retreat\nARKK owns more than $600 million stake of company in turmoil\n\nCathie Wood’s flagship exchange-traded fund pounced on a huge slump in Zillow ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-03/cathie-wood-s-ark-grabs-more-zillow-as-real-estate-firm-slumps\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZG":"Zillow Class A","ARKW":"ARK Next Generation Internet ETF","ARKF":"ARK Fintech Innovation ETF","ARKK":"ARK Innovation ETF","Z":"Zillow"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-03/cathie-wood-s-ark-grabs-more-zillow-as-real-estate-firm-slumps","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180751345","content_text":"Flagship innovation fund added shares amid Tuesday retreat\nARKK owns more than $600 million stake of company in turmoil\n\nCathie Wood’s flagship exchange-traded fund pounced on a huge slump in Zillow Group Inc. to add more shares of the embattled real estate company.\nThe ARK Innovation ETF (ticker ARKK) bought 288,813 shares of the property firm on Tuesday, according to the daily trading update from Wood’s Ark Investment Management. Zillow plunged over 10% on the day after pulling the plug on its tech-powered home-flipping operation.\nArk’s purchases were worth around $25 million, based on the closing price.\n\nZillow was down again in early trading on Wednesday. The Seattle-based company plans to take writedowns of as much as $569 million and reduce its workforce by 25% as it ditches the algorithm-driven business in the coming months, it said.\nWood is well known for buying the dip in her high-conviction bets. She and her firm frequently emphasize they have at least a five-year investment horizon, and acknowledge that the disruptive companies they target are often volatile.\nAfter delivering a 153% return last year, ARKK has lost about 1% in 2021. While its largest holding Tesla Inc. has soared, the fund has been dragged down by other top picks including Zillow, Roku Inc. and Zoom Video Communications Inc.\nThe $21.8 billion ARKK owns around 7.1 million shares in Zillow worth more than $600 million, according to data compiled by Bloomberg. Wood also owns stakes via the $3.4 billion ARK Fintech Innovation ETF (ARKF) and the $5.6 billion ARK Next Generation Internet ETF (ARKW), making her firm Zillow’s fifth-largest shareholder.\nThe daily trading updates from Ark show only active decisions by the management team and do not include creation or redemption activity caused by investor flows. For that reason, the firm’s exact trading activity may vary.","news_type":1,"symbols_score_info":{"ARKF":0.9,"ARKK":0.9,"ARKW":0.9,"Z":0.9,"ZG":0.9}},"isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846300419,"gmtCreate":1636044189280,"gmtModify":1636047737141,"author":{"id":"4097808049246230","authorId":"4097808049246230","name":"Eagleeyes","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097808049246230","authorIdStr":"4097808049246230"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>good opportunity to buy some MRNA today. Hold it until next quarter, with vaccine booster rolls out in the near future expect MRNA to go back to 350 level","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>good opportunity to buy some MRNA today. Hold it until next quarter, with vaccine booster rolls out in the near future expect MRNA to go back to 350 level","text":"$Moderna, Inc.(MRNA)$good opportunity to buy some MRNA today. Hold it until next quarter, with vaccine booster rolls out in the near future expect MRNA to go back to 350 level","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846300419","isVote":1,"tweetType":1,"viewCount":1004,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848082328,"gmtCreate":1635948310509,"gmtModify":1635948341793,"author":{"id":"4097808049246230","authorId":"4097808049246230","name":"Eagleeyes","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097808049246230","authorIdStr":"4097808049246230"},"themes":[],"htmlText":"Buy other related vaccine stock like AZN.","listText":"Buy other related vaccine stock like AZN.","text":"Buy other related vaccine stock like AZN.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848082328","repostId":"1128259542","repostType":4,"isVote":1,"tweetType":1,"viewCount":346,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848089377,"gmtCreate":1635948138366,"gmtModify":1635948138434,"author":{"id":"4097808049246230","authorId":"4097808049246230","name":"Eagleeyes","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097808049246230","authorIdStr":"4097808049246230"},"themes":[],"htmlText":"Pfizer best earnings, stock gapped&nbsp;up.To buy other vaccine stock such as AZN. Good&nbsp; &nbsp; &nbsp;opportunity to profit.","listText":"Pfizer best earnings, stock gapped&nbsp;up.To buy other vaccine stock such as AZN. Good&nbsp; &nbsp; &nbsp;opportunity to profit.","text":"Pfizer best earnings, stock gapped up.To buy other vaccine stock such as AZN. Good opportunity to profit.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848089377","repostId":"2180756676","repostType":4,"repost":{"id":"2180756676","kind":"highlight","pubTimestamp":1635936538,"share":"https://ttm.financial/m/news/2180756676?lang=&edition=full","pubTime":"2021-11-03 18:48","market":"us","language":"en","title":"This News May Top Anything Else Moderna Says During Its Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2180756676","media":"Motley Fool","summary":"Moderna's (NASDAQ:MRNA) third-quarter earnings report on Thursday is sure to be chock-full of exciti","content":"<p><b>Moderna</b>'s (NASDAQ:MRNA) third-quarter earnings report on Thursday is sure to be chock-full of exciting numbers and news. Investors are expecting another billion-dollar quarter. That's thanks to sales of the company's coronavirus vaccine. And&nbsp;I'll be watching for details -- such as future vaccine orders -- that could determine Moderna's path moving forward.</p>\n<p>But no matter what Moderna has to say, it will be difficult to top something the company announced last week. Why? This news brings a potential blockbuster product one major step closer to commercialization. In fact, this candidate's next step should be a regulatory submission. Let's take a closer look at what may be Moderna's next billion-dollar revenue driver.</p>\n<h2>The next big product</h2>\n<p>Last week, Moderna said it dosed the first participant in the phase 3 pivotal trial of its cytomegalovirus (CMV) vaccine candidate. This could become Moderna's next big product. CMV is a common virus. For many people it doesn't develop into something serious. But for others, CMV could be devastating. Unborn babies and people with weakened immune systems are most at risk.</p>\n<p>An approved vaccine currently doesn't exist for CMV. And the development programs of most potential competitors are earlier- stage. This means success could offer Moderna the first-to-market advantage. Moderna estimates peak annual revenue for an eventual CMV vaccine would be between $2 billion and $5 billion.</p>\n<p>So, this could be an extremely important product for the biotech company. And as I always say about getting to market first, if healthcare providers are satisfied with the product, they are likely to stick with it.</p>\n<p>Data so far are promising. Moderna's CMV candidate includes six mRNAs that encode for two viral proteins needed to infect. This technique prepares the body to produce an immune response against both proteins.</p>\n<p>Now, exactly how far from commercialization is Moderna? We might think back to coronavirus vaccine development and expect a similar path for the CMV candidate. Unfortunately, investors will have to wait longer this time around. I'll explain.</p>\n<h2>Coronavirus vaccine versus CMV vaccine candidate</h2>\n<p>Coronavirus vaccine development benefited from two elements. First, it was easier than usual to enroll volunteers in clinical trials. Considering the pandemic, many people were eager to try a vaccine -- even in experimental stages. Outside of such extreme situations, it isn't always easy to quickly find participants for a clinical trial.</p>\n<p>That's why it may take longer to enroll a CMV vaccine trial than a coronavirus vaccine one, even if the target number of participants is much lower. For example, for CMV, Moderna plans on enrolling 8,000 participants across 150 sites globally. Moderna enrolled about 30,000 volunteers in its phase 3 coronavirus vaccine trial.</p>\n<p>The second reason the CMV candidate may take longer to reach the market: The U.S. Food and Drug Administration (FDA) offered a fast path to market for COVID-19 vaccine candidates -- Emergency Use Authorization (EUA). The FDA only offers EUAs during public health emergencies such as pandemics. That shortens review time from as long as 10 months to just a few weeks. Moderna, of course, can't apply for emergency authorization for the CMV candidate. So, the potential vaccine won't make it to market nearly as quickly as the coronavirus vaccine.</p>\n<p>What does this mean for investors? We're all interested in Moderna's latest sales and profit numbers. And we want to know what lies ahead for the coronavirus vaccine program. But what may be most important is the next big revenue and profit driver down the road -- outside of the coronavirus program. And if all goes smoothly, that could be the CMV vaccine candidate.</p>\n<p>That's why investors should keep a close eye on any comments from Moderna about its CMV program -- from trial data to regulatory request timeframe. This candidate may be key to Moderna's transformation from coronavirus vaccine company to an mRNA giant that can cover a wide variety of therapeutic areas.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This News May Top Anything Else Moderna Says During Its Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis News May Top Anything Else Moderna Says During Its Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 18:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/03/this-news-may-top-moderna-earnings-news/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna's (NASDAQ:MRNA) third-quarter earnings report on Thursday is sure to be chock-full of exciting numbers and news. Investors are expecting another billion-dollar quarter. That's thanks to sales ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/03/this-news-may-top-moderna-earnings-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/11/03/this-news-may-top-moderna-earnings-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180756676","content_text":"Moderna's (NASDAQ:MRNA) third-quarter earnings report on Thursday is sure to be chock-full of exciting numbers and news. Investors are expecting another billion-dollar quarter. That's thanks to sales of the company's coronavirus vaccine. And I'll be watching for details -- such as future vaccine orders -- that could determine Moderna's path moving forward.\nBut no matter what Moderna has to say, it will be difficult to top something the company announced last week. Why? This news brings a potential blockbuster product one major step closer to commercialization. In fact, this candidate's next step should be a regulatory submission. Let's take a closer look at what may be Moderna's next billion-dollar revenue driver.\nThe next big product\nLast week, Moderna said it dosed the first participant in the phase 3 pivotal trial of its cytomegalovirus (CMV) vaccine candidate. This could become Moderna's next big product. CMV is a common virus. For many people it doesn't develop into something serious. But for others, CMV could be devastating. Unborn babies and people with weakened immune systems are most at risk.\nAn approved vaccine currently doesn't exist for CMV. And the development programs of most potential competitors are earlier- stage. This means success could offer Moderna the first-to-market advantage. Moderna estimates peak annual revenue for an eventual CMV vaccine would be between $2 billion and $5 billion.\nSo, this could be an extremely important product for the biotech company. And as I always say about getting to market first, if healthcare providers are satisfied with the product, they are likely to stick with it.\nData so far are promising. Moderna's CMV candidate includes six mRNAs that encode for two viral proteins needed to infect. This technique prepares the body to produce an immune response against both proteins.\nNow, exactly how far from commercialization is Moderna? We might think back to coronavirus vaccine development and expect a similar path for the CMV candidate. Unfortunately, investors will have to wait longer this time around. I'll explain.\nCoronavirus vaccine versus CMV vaccine candidate\nCoronavirus vaccine development benefited from two elements. First, it was easier than usual to enroll volunteers in clinical trials. Considering the pandemic, many people were eager to try a vaccine -- even in experimental stages. Outside of such extreme situations, it isn't always easy to quickly find participants for a clinical trial.\nThat's why it may take longer to enroll a CMV vaccine trial than a coronavirus vaccine one, even if the target number of participants is much lower. For example, for CMV, Moderna plans on enrolling 8,000 participants across 150 sites globally. Moderna enrolled about 30,000 volunteers in its phase 3 coronavirus vaccine trial.\nThe second reason the CMV candidate may take longer to reach the market: The U.S. Food and Drug Administration (FDA) offered a fast path to market for COVID-19 vaccine candidates -- Emergency Use Authorization (EUA). The FDA only offers EUAs during public health emergencies such as pandemics. That shortens review time from as long as 10 months to just a few weeks. Moderna, of course, can't apply for emergency authorization for the CMV candidate. So, the potential vaccine won't make it to market nearly as quickly as the coronavirus vaccine.\nWhat does this mean for investors? We're all interested in Moderna's latest sales and profit numbers. And we want to know what lies ahead for the coronavirus vaccine program. But what may be most important is the next big revenue and profit driver down the road -- outside of the coronavirus program. And if all goes smoothly, that could be the CMV vaccine candidate.\nThat's why investors should keep a close eye on any comments from Moderna about its CMV program -- from trial data to regulatory request timeframe. This candidate may be key to Moderna's transformation from coronavirus vaccine company to an mRNA giant that can cover a wide variety of therapeutic areas.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":450,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}